表紙
市場調査レポート

脊髄損傷:パイプライン分析

Spinal Cord Injury - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 229793
出版日 ページ情報 英文 228 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
脊髄損傷:パイプライン分析 Spinal Cord Injury - Pipeline Review, H1 2016
出版日: 2016年05月25日 ページ情報: 英文 228 Pages
概要

脊髄損傷は、脊髄が身体的外傷を受けたものであると定義され、運動機能や感覚が失われたり障害が残ったりします。通常、身体的外傷や疾患(横断性脊髄炎、ポリオ、脊椎破裂、フリードライヒ運動失調症)によって引き起こされます。 事故後に現れるこの疾患の緊急的な兆候は、背中に激しい痛みが起こる、首や頭、あるいは背中に圧迫感がある、体のどこかの力が抜けたり、感覚が無くなる、手、指、足、つま先がしびれたり感覚が無くなる、膀胱や腸のコントロールがきかなくなる、バランスを取り歩くのが困難になる、事故後に呼吸障害が起きる、首や背中が奇妙な形になったりねじれたりします。

当レポートでは、脊髄損傷の治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

イントロダクション

  • 調査範囲

脊髄損傷 概要

治療薬の開発

  • パイプライン製品;概要
  • パイプライン製品;比較分析

企業で開発中の治療薬

大学/機関で研究中の治療薬

パイプライン製品の概況

  • 臨床段階の製品
  • 初期段階の製品

企業で開発中の製品

大学/機関で研究中の製品

治療薬開発に従事している企業

  • Acorda Therapeutics, Inc.
  • Asterias Biotherapeutics, Inc.
  • Asubio Pharma Co., Ltd.
  • Athersys, Inc.
  • BioArctic Neuroscience AB
  • BioAxone BioSciences, Inc.
  • FirstString Research, Inc.
  • Genervon Biopharmaceuticals, LLC
  • Histocell S.L.
  • Kadimastem Ltd. .
  • Kringle Pharma, Inc.
  • Lipopharma Therapeutics SL
  • Lpath, Inc.
  • MandalMed, Inc.
  • Mapreg S.A.S.
  • Neuralstem, Inc.
  • Neuronax SAS
  • New World Laboratories, Inc.
  • Omeros Corporation
  • PharmatrophiX, Inc.
  • Pharmicell Co., Ltd.
  • Protagenic Therapeutics Inc.
  • Q Therapeutics, Inc.
  • Remedy Pharmaceuticals, Inc.
  • RespireRx Pharmaceuticals Inc.
  • RhinoCyte, Inc.
  • SanBio, Inc.
  • Sirnaomics, Inc.
  • StemCells, Inc.
  • Stemedica Cell Technologies, Inc.
  • TissueGene, Inc.
  • Tumorend, LLC
  • Vertex Pharmaceuticals Incorporated
  • Vicore Pharma AB

治療薬の評価

  • 単剤製品
  • 併用製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

最近のパイプライン動向

休止中のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8004IDB

Summary

Global Markets Direct's, 'Spinal Cord Injury - Pipeline Review, H1 2016', provides an overview of the Spinal Cord Injury pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Spinal Cord Injury, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Spinal Cord Injury and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Spinal Cord Injury
  • The report reviews pipeline therapeutics for Spinal Cord Injury by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Spinal Cord Injury therapeutics and enlists all their major and minor projects
  • The report assesses Spinal Cord Injury therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Spinal Cord Injury

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Spinal Cord Injury
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Spinal Cord Injury pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
  • Introduction
  • Spinal Cord Injury Overview
  • Therapeutics Development
  • Spinal Cord Injury - Therapeutics under Development by Companies
  • Spinal Cord Injury - Therapeutics under Investigation by Universities/Institutes
  • Spinal Cord Injury - Pipeline Products Glance
  • Spinal Cord Injury - Products under Development by Companies
  • Spinal Cord Injury - Products under Investigation by Universities/Institutes
  • Spinal Cord Injury - Companies Involved in Therapeutics Development
  • Spinal Cord Injury - Therapeutics Assessment
  • Drug Profiles
  • Spinal Cord Injury - Recent Pipeline Updates
  • Spinal Cord Injury - Dormant Projects
  • Spinal Cord Injury - Discontinued Products
  • Spinal Cord Injury - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Spinal Cord Injury, H1 2016
  • Number of Products under Development for Spinal Cord Injury - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Development by Companies, H1 2016 (Contd..1)
  • Number of Products under Development by Companies, H1 2016 (Contd..2)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Development by Companies, H1 2016 (Contd..2)
  • Products under Investigation by Universities/Institutes, H1 2016
  • Spinal Cord Injury - Pipeline by Acorda Therapeutics, Inc., H1 2016
  • Spinal Cord Injury - Pipeline by Asterias Biotherapeutics, Inc., H1 2016
  • Spinal Cord Injury - Pipeline by Asubio Pharma Co., Ltd., H1 2016
  • Spinal Cord Injury - Pipeline by Athersys, Inc., H1 2016
  • Spinal Cord Injury - Pipeline by BioArctic Neuroscience AB, H1 2016
  • Spinal Cord Injury - Pipeline by BioAxone BioSciences, Inc., H1 2016
  • Spinal Cord Injury - Pipeline by FirstString Research, Inc., H1 2016
  • Spinal Cord Injury - Pipeline by Genervon Biopharmaceuticals, LLC, H1 2016
  • Spinal Cord Injury - Pipeline by Histocell S.L., H1 2016
  • Spinal Cord Injury - Pipeline by Kadimastem Ltd., H1 2016
  • Spinal Cord Injury - Pipeline by Kringle Pharma, Inc., H1 2016
  • Spinal Cord Injury - Pipeline by Lipopharma Therapeutics SL, H1 2016
  • Spinal Cord Injury - Pipeline by Lpath, Inc., H1 2016
  • Spinal Cord Injury - Pipeline by MandalMed, Inc., H1 2016
  • Spinal Cord Injury - Pipeline by Mapreg S.A.S., H1 2016
  • Spinal Cord Injury - Pipeline by Neuralstem, Inc., H1 2016
  • Spinal Cord Injury - Pipeline by Neuronax SAS, H1 2016
  • Spinal Cord Injury - Pipeline by New World Laboratories, Inc., H1 2016
  • Spinal Cord Injury - Pipeline by Omeros Corporation, H1 2016
  • Spinal Cord Injury - Pipeline by PharmatrophiX, Inc., H1 2016
  • Spinal Cord Injury - Pipeline by Pharmicell Co., Ltd., H1 2016
  • Spinal Cord Injury - Pipeline by Protagenic Therapeutics Inc., H1 2016
  • Spinal Cord Injury - Pipeline by Q Therapeutics, Inc., H1 2016
  • Spinal Cord Injury - Pipeline by Remedy Pharmaceuticals, Inc., H1 2016
  • Spinal Cord Injury - Pipeline by RespireRx Pharmaceuticals Inc., H1 2016
  • Spinal Cord Injury - Pipeline by RhinoCyte, Inc., H1 2016
  • Spinal Cord Injury - Pipeline by SanBio, Inc., H1 2016
  • Spinal Cord Injury - Pipeline by Sirnaomics, Inc., H1 2016
  • Spinal Cord Injury - Pipeline by StemCells, Inc., H1 2016
  • Spinal Cord Injury - Pipeline by Stemedica Cell Technologies, Inc., H1 2016
  • Spinal Cord Injury - Pipeline by TissueGene, Inc., H1 2016
  • Spinal Cord Injury - Pipeline by Tumorend, LLC, H1 2016
  • Spinal Cord Injury - Pipeline by Vertex Pharmaceuticals Incorporated, H1 2016
  • Spinal Cord Injury - Pipeline by Vicore Pharma AB, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Spinal Cord Injury Therapeutics - Recent Pipeline Updates, H1 2016
  • Spinal Cord Injury - Dormant Projects, H1 2016
  • Spinal Cord Injury - Dormant Projects (Contd..1), H1 2016
  • Spinal Cord Injury - Dormant Projects (Contd..2), H1 2016
  • Spinal Cord Injury - Dormant Projects (Contd..3), H1 2016
  • Spinal Cord Injury - Dormant Projects (Contd..4), H1 2016
  • Spinal Cord Injury - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Spinal Cord Injury, H1 2016
  • Number of Products under Development for Spinal Cord Injury - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Top 10 Molecule Types, H1 2016
  • Number of Products by Stage and Top 10 Molecule Types, H1 2016
Back to Top